Palantir stock volatility amid growth vs. valuation tension; Q2 earnings Aug 3; Michael Burry short; open-source rival emerges
Key Questions
Why has Palantir stock been volatile recently?
Palantir shares are down 28% year-to-date and fell 6.1% on July 22 amid tension between strong growth and high valuation. Options markets price in a potential 15% swing around the upcoming earnings report.
When is Palantir reporting Q2 earnings?
Palantir is scheduled to release its second-quarter results on August 3, which is viewed as a key catalyst for the stock. Analysts expect significant movement based on commercial bookings trends and growth outlook.
What are Oppenheimer's expectations for Palantir's Q2 results?
Oppenheimer anticipates a beat and raise, forecasting $0.34 EPS and $1.81 billion in revenue with 85% growth while rebutting fears of LLM disruption. The firm reiterated its positive stance ahead of the report.
What is Michael Burry's stance on Palantir stock?
Michael Burry has doubled down on his short position in Palantir ahead of the August 3 earnings release. This adds to bearish sentiment alongside concerns over slowing commercial backlog growth.
What key metric should investors watch in Palantir's earnings?
Stabilization in commercial bookings is considered the most important metric following recent reports of deceleration from 21% to 12% growth. Analysts will also focus on overall revenue and guidance updates.
What are the current analyst ratings and price targets for Palantir?
Citi maintains a Buy rating but trimmed its target to $200 after raising its FY2027 revenue growth estimate to 53%. D.A. Davidson upgraded the stock to Buy with a $175 price target.
How does Palantir's valuation compare to its fundamentals?
The stock trades at 85x forward earnings while a DCF model suggests a fair value around $150.64, highlighting ongoing valuation tension. Benzinga Edge scores show a high growth rank of 98 but a low value rank of 2.41.
What are the technical support and resistance levels for Palantir stock?
Benzinga Edge identifies support at $122.50 and resistance at $136.50. Insider selling has continued amid these levels and broader market pressures.
Stock down ~22.6% YTD, fell 6.1% on July 22 (Cleveland Research weak commercial spending hint) and dropped 10% on [date] amid AI sell-off and NHS effectiveness study. Q2 earnings Aug 3 key catalyst; options imply 9.6% swing. Analyst targets range $70-$255, mean $182.20. Oppenheimer expects beat and raise with $0.34 EPS, $1.81B revenue, 85% growth, reiterates Outperform $200 PT. Commercial bookings stabilization is key metric. Michael Burry doubled down on short. Benzinga Edge ranks growth 98, value 2.41, support $122.50, resistance $136.50. Citi raised FY2027 revenue growth estimate to 53%, maintaining Buy but trimming target to $200. D.A. Davidson upgraded to Buy with $175 target. Valuation tension persists: 78.9x forward earnings vs DCF $150.64; GuruFocus GF Value $143.19 flags 8.9% undervaluation. Insider selling continues (109 sales, 0 buys; $156.7M in 3 months). A bearish options trader cites slowing commercial backlog growth (12% vs 21%). Recent: stock popped 7% on July 27; reclaimed 50-day MA, up 13.7% over four weeks; analyst expects Q2 beat with 85% sales growth vs 79% guidance; conflicting fair value estimates ($107 vs $173) highlight valuation debate ahead of earnings. Options flow on July 27 showed 389K contracts, 68% calls, notable $140 strike activity. Preview estimates Q2 government revenue at $1.03B total. Trefis analysis reverse-engineers 138x P/E to require 31% revenue CAGR over 7 years, below current 68% pace, reinforcing valuation fragility. Zacks recap confirms 13.68% monthly gain and Aug 3 earnings date. Amundi lifted stake by 2.5% in Q1, a modest positive institutional signal.